India ranked by international pharma as the third most competitive nation

19 Nov 2017

Perception of India’s API manufacturing seems to be improving.

CPhI & P-MEC India – organised by UBM – is set to welcome more than 50,000 attendees as the CPhI Global Pharma Index shows the country’s efforts to improve its reputation are paying dividends. India emerged successful in a number of key areas and was ranked by international pharma companies as the third most competitive nation globally.

India ranked by international pharma as the third most competitive nation

The inaugural CPhI Global Pharma Index – a reputation audit – draws on the insights of 500 international pharmaceutical companies from over 40 countries to rank the major pharma economies out of 10 across a spread of criteria.

These findings are announced in the 11th annual CPhI & P-MEC India 2017 is set to open later this month in Mumbai (27-30 November 2017). It is a key time for the Indian industry, with the second India Pharma Week returning (25-30 November 2017), which will feature seven events covering the entire pharma supply chain in India, leveraging Mumbai’s status as a major pharma hub. Such has been the growth in India over the last year, CPhI & P-MEC India now runs across two exhibition centres simultaneously ­­– the Bombay Exhibition Centre (BEC) and the MMRDA Grounds (BKC) – and has expanded from a three- to a four- day event.

Encouragingly, India was rated second globally for predicted ‘pharma market growth potential’, with respondents citing high growth domestic markets and expanding manufacturing exports as key drivers. India received a score of 7.0, narrowly behind China (7.2). However, India was rated by pharmaceutical companies as having nearly twice the potential of Western European countries, significantly outpacing even the US (6.3), Korea (6), and Germany (5.9), who finished third, fourth, and fifth respectively.

In fact, the confidence in India was such that the country was chosen as the third most competitive pharma business destination, with a score of 6.3, behind only the US (6.9) and Germany (6.6), but ahead of Japan and – chief rival – China.

India’s recent efforts to increase pharmaceutical manufacturing quality also appear to be having an effect. The perception of India’s API manufacturing seems to be improving, with the industry believing India is broadly comparable to Italy, Spain, and Korea, though it is still behind tier one nations such as Germany and the US.

For ‘quality and knowledge’ of pharmaceutical professionals, India (6.2) came notably ahead of China, Korea and Spain, and at a comparable level to that of Italy (6.5). Interestingly, and perhaps highlighting India’s efforts in patented and biosimilar drug development, the country also demonstrated growth in the category of ‘innovativeness’, which remains a key component for the creation of new medicines. In this category, India finished a little behind Korea and France, and ahead of Italy and Spain.

A more detailed analysis of only domestic respondents showed that the vast majority (80%) were either ‘confident’ or ‘extremely confident’ in their business outlook for India’s market in 2018. Notably, the CPhI report also found that 88% of respondents in India ‘were looking to work with foreign partners in 2018’, with on average 50% of sales to foreign companies. Highlighting this increased internationalization, exhibitor numbers have grown by more than 200 companies in the last year, with the 2017 event featuring 1400 exhibitors from over 100 countries.

“Ultimately, the fundamentals of progression in the country are extremely strong – boasting over 24,000 pharmaceutical companies, and 10,500 plants – coupled with Government support, increased investment and an improving regulatory reputation, there is a real sense amongst attendees at CPhI & P-MEC India that the country’s pharma sector is preparing to enter the next stage in its advancement. This event is the perfect place for companies to explore the latest trends and innovations the market has to offer and meet the movers and shakers in the domestic and international pharma machinery, technology and ingredients industries,” commented Rutger Oudejans, Brand Director Pharma at UBM.

Read More

Related news

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

Drivers behind Saudi Arabia’s forecast 10.74 $billion 2022 market

9 Sep 2019

Growing population, increase in non-communicable diseases and major investment in new hospitals, clinics and treatments driving growth.

Read more 
Take part in pharma’s largest reputation survey

Take part in pharma’s largest reputation survey

6 Sep 2019

Use your voice to shape CPhI Worldwide's third annual global survey of the major trends, changes and developments in the industry.

Read more 
Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Meet Avivia / Excipia at booth B56 Hall 12.1 CPhI Frankfurt 2019

29 Aug 2019

Meet Avivia at booth B56 Hall 12.1 CPhI Frankfurt 2019

Read more 
Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

Switzerland overtakes Germany as Europe’s biggest drug delivery innovator

16 Aug 2019

Pipeline of new drugs has helped drive increased innovation in packaging and drug delivery devices.

Read more 
Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

Growing domestic manufacturing creates new opportunities for international pharma in the Middle East

5 Aug 2019

Opportunities abound at CPhI MEA and experts anticipate regional generic companies acting as CMOs for international companies looking to enter the region.

Read more 
Drive for generics sees Korea increasingly attractive to international pharma

Drive for generics sees Korea increasingly attractive to international pharma

31 Jul 2019

Korean companies are opening more facilities overseas and using CPhI Korea to look for new international partners.

Read more 
Huge CPhI & P-MEC China a direct result of surging manufacturing

Huge CPhI & P-MEC China a direct result of surging manufacturing

22 Jul 2019

Great Hall of China: Informa adds additional capacity to Asia’s largest pharma event with record 66,000+ visits from 141 countries.

Read more 
Fresh data on protein interactions in Alzheimer’s disease

Fresh data on protein interactions in Alzheimer’s disease

2 Jul 2019

Demonstrates the unique ability of diffusional sizing to assess protein binding in-solution and for difficult-to-study systems.

Read more 
Piramal expands its high potency API capability

Piramal expands its high potency API capability

25 Jun 2019

Becomes one of only a few companies in the contract development and manufacturing market that can produce HPAPIs at such low OELs.

Read more 
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

Inaugural Bio Integrates conference highlights industry's inefficiency in developing products

18 Jun 2019

Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.

Read more